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In studies in murine models, active suppression by IL-10-secreting Foxp3 regulatory
T cells (Tregs) has emerged as an essential mechanism in colon homeostasis. However,
the role of the equivalent subset in humans remains unclear, leading to suggestions that
other subsets and/or mechanisms may substitute for Foxp3 Tregs in the maintenance of
colon homeostasis. We recently described a new subset of CD4CD8αα T cells reactive to
the gut bacterium Faecalibacterium prausnitzii and endowed with regulatory/suppressive
functions. This subset is abundant in the healthy colonic mucosa, but less common in
that of patients with inflammatory bowel disease (IBD). We discuss here the physiological
significance and potential role of these Tregs in preventing inflammation of the gut mucosa
and the potential applications of these discoveries for IBD management.
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DIVERSITY OF PERIPHERALLY DERIVED Tregs (pTregs)
CD4 regulatory T cells (Tregs) inhibit inflammatory responses (1). They can be subdivided into
natural Tregs, which differentiate in the thymus (tTreg) and peripherally derived Tregs (pTregs),
which differentiate in secondary lymphoid organs or tissues (2). These populations differ in
terms of their non-redundant roles: tTregs play an essential role in maintaining tolerance toward
self-structures, whereas pTregs are involved in the responses to externally delivered antigens or
commensal microbes. Furthermore, the tTreg population appears to be stable, whereas that of
pTregs may be more labile (3). This functional dichotomy results from differences in differentiation
due to exposure to different TCR ligands (self and non-self antigens, respectively) and specific
factors (cytokines, route of exposure, and antigen-presenting cells) in contrasting settings (4). The
two Treg subsets can also be distinguished on the basis of the presence or absence of constitutive
expression of the Foxp3 transcription factor. Constitutive Foxp3 expression and more particularly,
the demethylation of a specific region of the Foxp3 locus are characteristic features of tTregs (5).
Three main subsets of CD4 pTregs have been described in mice: Foxp3+CD25+ lymphocytes (3,
6), which are particularly abundant in the colon lamina propria (LP) (7) and two Foxp3  subsets:
the type 1 regulatory T (Tr1) cells and the T helper 3 (Th3) cells. The Tr1 subset secretes IL-10 and
TGF-β in the absence of IL-4 and IL-17 (8–10) and is abundant in the small intestine (7). The Th3
subset may also secrete IL-10, but it differs from Tr1 in its expression of membrane-bound TGF-β
(11, 12). The Tr1 Tregs are induced in vitro by IL-10 (8–10) and in vivo by TGF-β and IL-27 (9, 13)
in the context of diverse immune responses (14) and upon chronic stimulation with antigens in the
presence of IL-10 (10). The suppressive action of Tr1 Tregs is essentially IL-10-dependent, but it is
also at least partly governed by TGF-β (8, 9).Moreover, the suppressive function of these cellsmay be
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mediated by a cytotoxic mechanism dependent on granzyme B
and perforin (15). The Th3 subset is induced in the gut mucosa by
oral immunization (12, 13). Its suppressive effects are essentially
mediated by TGF-β, but also partly by IL-10 (11, 16). Much
remains unknown about the typical features of Tr1 and Th3 cells
and their relative contributions to immune regulation in general
and to gut homeostasis in particular. Recent studies have shown
that the development of colonic Foxp3+ Tregs in mice is induced
by gut clostridial bacteria and their metabolites, and that these
Tregs play a key role in the prevention of colitis (17, 18). In
humans, however, the role of gut Foxp3+ Tregs in irritable bowel
disease (IBD) remains unclear (19, 20), leading to suggestions that
these cells may be less crucial in humans than in mice for the
maintenance of colon homeostasis (21, 22).
HUMAN COLON DP8α T CELLS ARE
pTregs INDUCED BY CLOSTRIDIAL
BACTERIA
We recently reported that the CD4CD8αα (DP8α) lymphocytes
of the colon LP are Foxp3  IL-10-secreting Tregs highly skewed
toward the recognition of Faecalibacterium prausnitzii, a gut bac-
terium belonging to cluster IV of the genus Clostridum (23). In
the healthy colonic mucosa of colon cancer patients, these cells
account for about 12% of the CD4 lymphocytes present. We have
shown that about 2% of the CD4 PBLs have the same CD4CD8αα
phenotype and that 15% of these cells, on average, also react with
F. prausnitzii (23). Together with the role of clostridial antigens in
the induction of mouse colonic Tregs (17, 24) and the demonstra-
tion that segmented filamentous bacteria (SFB) antigens induce
Th17 lymphocytes in the small intestine (25), our data suggest that
F. prausnitzii participates in the induction of humanDP8α colonic
Tregs through antigen presentation. Support for this hypothesis is
provided by our recent observation that F. prausnitzii imprints a
phenotypic tolerogenic profile including a failure to secrete IL-12
on LPS-matured humanDCs in vitro (unpublished data). Interest-
ingly, F. prausnitzii is the most abundant bacterium of the human
intestinal microbiota in healthy adults (26, 27) and decreases in
its abundance have been linked to dysbiosis in IBD (28–32). The
unique anti-inflammatory potential of this bacterium has recently
been demonstrated, both in vitro and in vivo (33, 34). We found
that there were fewer DP8α Tregs in the inflamed colonic mucosa
and blood of Crohn’s disease patients and in the blood of ulcerative
colitis (UC) patients than in healthy individuals (23). These results
suggest that lower levels of F. prausnitzii are associated with lower
levels of F. prausnitzii-specific Treg anti-inflammatory activity
in IBD patients, and that this may contribute to the disease. As
a corollary, this suggests that DP8α Tregs may play a role in
colon homeostasis and IBD prevention. However, this hypothesis
requires confirmation and a number of important questions about
these cells remain to be answered, to define more precisely their
contribution to IBD prevention.
DP8α Treg: A NEW pTreg SUBTYPE
We must first consider whether DP8α lymphocytes represent
a new pTreg subtype. If Tr1 cells are defined as Foxp3  Tregs
secreting IL-10, then DP8α T cells could be considered to be
Tr1 cells. Gagliani et al. (35) have suggested that human and
mouse Tr1 cells are defined by the coexpression of CD49b and
LAG3. We have also reported the expression of LAG3 by colonic
DP8α cells ex vivo (23), but we did not consider their expression
of CD49b. Nevertheless, our data revealed significant differences
between Tr1 cells and DP8α Tregs. For example, DP8α Tregs sta-
bly express the CD8αα homodimer, CD25 and the transcription
factor GATA-3, but do not express PD1, considered to be a canon-
ical marker of Tr1 cells (9, 35). Moreover, whereas suppression
by Tr1 and Th3 Tregs is largely dependent on IL-10 or TGF-β
secretion, respectively (7, 9), the inhibition of T-cell proliferation
by DP8α Tregs in vitro was little affected by a blocking anti-IL-
10 antibody and not at all affected by an anti-TGF-β receptor
antibody (23). It is, therefore, possible to distinguish DP8α Tregs
from the Tr1 and Th3 Treg subsets.
One surprising finding of our work is the lack of Foxp3 expres-
sion by DP8α Tregs. However, they otherwise strongly resemble
mouse Foxp3 colonic Tregs in terms of their regulatory mark-
ers (CD25, CTLA-4, GITR, and LAG3), regulatory functions
(inhibition of T-cell proliferation, inhibition of DC maturation,
and IL-10 secretion) and induction by related clostridial species
(23). In both mice and humans, Foxp3 expression is required
to maintain the Treg cell program and suppressive functions of
tTreg (36) by repressing the activation-dependent expression of
a number of genes, as elegantly shown in a recent study (37). In
mice, Foxp3 is also expressed by the pTregs induced by clostridial
bacteria (17). We have reported that DP8α Tregs have highly
stable regulatory properties (23). This implies a high degree of
commitment of these cells to their Treg status, with the expres-
sion of a Foxp3-independent genetic program in these cells. We
are currently trying to decipher the genetic basis of DP8αα
Treg commitment by comparing the transcriptomic signatures
of the three main subtypes of CD4 lymphocytes in the colon
LP: DP8α Tregs, conventional CD4 (CD4+CD25 CD127High),
and Foxp3 Tregs (CD4+CD25+CD127low), with and without
activation.
COLONIC DP8α Tregs: FUNCTIONAL
HOMOLOGS OF THE pTregs INDUCED BY
CLOSTRIDIAL BACTERIA IN MICE?
One important question raised by our results is whether human
DP8α Tregs are functional homologs of the mouse Foxp3 Tregs
induced by clostridial species (17), as shown in Figure 1. Alter-
natively, clostridial bacteria might induce both Treg subsets, with
these subset playing complementary roles in colon homeosta-
sis. This second hypothesis is unlikely in mice, because most
of the IL-10-secreting Tregs of the colon LP express Foxp3, so
IL-10-secreting Foxp3-negative lymphocytes are missing from
this compartment (7). CD4CD8αα IL-10-secreting T lympho-
cytes have been described in the mouse gut mucosa. However,
these cells were located in the epithelium of the small intes-
tine (38), a compartment clearly different from the colon in
terms of the composition and function of its immune com-
ponents (39). In addition, we found no reactivity to F. praus-
nitzii in freshly sorted human colonic Foxp3 Tregs, suggesting
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FIGURE 1 | Human CD4CD8αα (DP8α ) regulatory T cells (Treg): functional homologs of the Tregs induced by clostridial bacteria in mice? In mice and
humans, a subpopulation of CD4+ thymocytes develops into Tregs expressing the transcription factor Foxp3. These thymus-derived Tregs (tTregs) migrate to all
tissues, including the colonic mucosa, where they prevent autoimmune reactions. Thymus-derived naïve CD4+ T cells also migrate to the colonic mucosa. There,
depending on the type of antigen-dependent signals they receive, they develop into effector lymphocytes or peripherally induced Tregs (pTregs). It has been shown in
mice that colonic Th17 and Foxp3+ IL-10-secreting pTregs are induced by segmented filamentous bacteria (SFB) and clostridial bacteria, respectively. In the human
colonic mucosa, IL-10-secreting DP8α Tregs induced by Faecalibacterium prausnitzii (F. prausnitzii), a gut bacterium belonging to the Clostridium cluster IV, seem to
be the homologs of the mouse Foxp3 pTregs.
that this bacterium (or at least its antigens) is not involved in
the induction of Foxp3 lymphocytes in the human colon LP
(unpublished data). This may appear to conflict with the induc-
tion of Foxp3 Treg development by human clostridial bacteria
in the colonic mucosa of GF mice (24), but the true meaning
of this result remains unclear, because another study has shown
that the human microbiota cannot restore normal mouse colon
development upon transfer into GF animals (40). It, therefore,
appears possible that during evolution, both humans and rodents
have selected clostridial symbionts on the basis of their capac-
ity to maintain colon homeostasis via Treg induction, but that
these two groups diverged in terms of the molecular mech-
anisms involved in this process. Consistent with the hypoth-
esis that DP8α Tregs may be functional homologs of mouse
Foxp3 pTregs, the role of human Foxp3 Tregs in the preven-
tion of colitis remain unclear (19). Moreover, the manifesta-
tions of enteropathy in IPEX (immune dysregulation, polyen-
docrinopathy, enteropathy, X-linked syndrome) patients (who
lack functional Foxp3Treg), which are often considered to provide
support for a role for Foxp3+ Tregs in the prevention of IBD,
clearly differ from those in IBD (41). This suggests that IPEX-
associated colitis results from autoimmune attacks rather than
from defects in tolerance to the microbiota and, thus, that mech-
anisms other than Foxp3 Treg-dependent suppression, possibly
including suppression by DP8α Tregs, are involved in human
colonic homeostasis (21, 22).
ARE ALL BLOOD DP8α LYMPHOCYTES
REGULATORY T CELLS?
About 2% of CD4 PBLs have the same double-positive phenotype
as DP8α LPLs, raising questions about their function.Most DP8α
PBLs lacked regulatory markers ex vivo, but they acquired these
markers and regulatory functions after a short period of in vitro
activation or establishment in culture (which also requires TCR
activation), whereas their CD4 homologs did not. Moreover, ex
vivo, about 10% of DP8α PBLs expressed the gut homing receptor
CCR9, and about the same proportion recognized F. prausnitzii
(23). Therefore, most DP8α PBLs appear to be Tregs, although
only a limited fraction of these cells react to F. prausnitzii. It is
possible that some of these cells are pTregs induced by microbiota
components present outside the gut, in the pulmonary mucosa,
or the skin, for example. It is also possible that some of the
circulating DP8α lymphocytes are not Tregs. Additional studies
will be required to address these questions and to determine the
specificity of the TCRs of regulatory DP8α PBLs that do not
recognize F. prausnitzii.
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DOES THE CD8αα MOLECULE PLAY A
ROLE IN DP8α Treg FUNCTION?
CD8αα expression can be transiently induced on human CD4+
T lymphocytes by activation in the presence of IL-4 (42).However,
this molecule is expressed constitutively by the DP8α lympho-
cytes of the human colon LP and blood (23). This raises ques-
tions about the possible role of this molecule in DP8α Treg
function. Like the CD8αβ coreceptor, CD8αα binds to MHC
class-I molecules (43). In mice and humans, it also binds to the
specific ligands thymus leukemia antigen (TL) (44) and gp180
(CEACAM5)/CD1d (45, 46), respectively. The human CD8αα
ligand is expressed in the gut, by non-lymphoid cells, such as
colonic epithelial cells and polynuclear neutrophils, two types of
non-professional APCs that can activate MHC class II-restricted
T lymphocytes. Previous studies have shown that the interaction
between the CD8αα molecule and its ligands costimulates both
the TCR activation induced by specific MHC/Ag complexes or by
CD3 antibody, and T-cell function (44, 47). Moreover, CD8αα
has been shown to play a role in the selection of high-affinity
CD8αβ T cells (48).We have observed (unpublished data) that the
triggering of CD8αα by an anti-CD8 antibody (OKT8) enhances
the activation of DP8α Tregs induced by an anti-CD3 antibody
(OKT3). This suggests that ligation of the CD8αα molecule of
DP8α Tregs may increase their TCR-dependent activation by
microbiota-derived antigens. It has recently been shown that TCR
signaling is critical for themaintenance of the suppressive capacity
of Foxp3 Tregs in mice, particularly in the colonic mucosa (49).
It would be interesting to determine whether there is a similar
dependence on TCR signaling in DP8α Tregs and whether the
CD8αα receptor contributes to this process.
DP8α Tregs, BIOLOGICAL MARKERS AND
THERAPEUTIC TARGETS IN IBD
Our observation that DP8α Treg levels are low in the colonic LP
and blood of IBD patients, who frequently also have low levels of
F. prausnitzii in their gutmicrobiota, provides evidence in support
of a correlation between the levels of these bacteria and DP8α
Treg levels in these patients (Figure 2). As recently suggested (50),
such a correlation might result from a feedback loop between
the selection, by follicular regulatory T cells (Tfr), of an adequate
FIGURE 2 | Suggested model of DP8α Treg induction and homeostasis control in the human colonic mucosa. (A) In the colonic mucosa, F. prausnitzii
antigens are presented by dendritic cells. Simultaneously, these bacteria may imprint a tolerogenic phenotype on dendritic cells. The recognition of F. prausnitzii
antigens by the naïve CD4 T cells equipped with a specific TCR contributes, in this context, to the differentiation of these cells into Foxp3-lacking Tregs coexpressing
CD4 and CD8α. DP8α T lymphocytes express most of the regulatory markers of Foxp3 Tregs and secrete IL-10. A fraction of these cells migrate into the blood.
(B) Like Foxp3 Tregs, DP8α Tregs inhibit the maturation of dendritic cells in a CTLA-4- and LFA-1-dependent manner. Moreover, these cells decrease effector T-cell
proliferation, via a mechanism involving interleukin 10. (C) Under normal circumstances, colonic F. prausnitzii expands the pool of DP8α Tregs in the colonic mucosa
and in the blood; in IBD patients, the low levels of F. prausnitzii may compromise the expansion or survival of the DP8α Treg population, reducing the frequency of
these cells in the mucosa and blood of patients.
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IgA repertoire fostering microbiota diversity, particularly as con-
cerns the abundance of clostridial bacteria, which in turn govern
the development or survival of DP8α Tregs. In this context, the
possible presence of DP8α Tfr should be investigated.
It is currently difficult to determine whether there is a strong
correlation between the levels of DP8α Tregs and F. prausnitzii
in the colonic mucosa, as no method for quantifying DP8α lym-
phocytes in biopsy specimens is available. There is an urgent need
to develop such a method, based on CD4 and CD8α colabeling
by immunohistochemistry, although this approach would not dis-
tinguish between CD4CD8αα and CD4CD8αβ lymphocytes, or,
preferentially, quantitative RT-PCR, if a specific marker of colonic
DP8α lymphocytes can be identified from the transcriptomic
signature of these cells. Efforts are currently beingmade to identify
such a marker.
Only about 15% of DP8α PBLs appear to be specific for F.
prausnitzii, suggesting that the remaining circulating DP8α lym-
phocytes are not induced by the gut microbiota. Nevertheless, the
total frequency of DP8α PBL and the frequency of these cells for F.
prausnitzii are lower in the blood of IBD patients than in controls
(23). The question as to whether the frequency of circulating
DP8α lymphocytes and/or of DP8α lymphocytes reactive to F.
prausnitzii can be viewed as a biological marker of IBD is an
important issue as there are currently no specific biomarkers of
this disease. It will be necessary to determine whether DP8α
levels are correlated with disease type and activity and predict
disease progression in a large cohort of IBD patients to answer this
question.
If DP8α levels in the blood or the colonic mucosa are found
to be predictive of disease progression, this would provide an
objective means of assessing the contribution of these Tregs to
the prevention of IBD. Such an advance would open up new
possibilities for treating IBD by manipulating the frequency of
F. prausnitzii in the gut microbiota or increasing the number of
circulating DP8α Tregs through specific in vivo stimulation or
induction, or adoptive transfers of these cells. We have found
that DP8α Tregs proliferate well in vitro, whilst maintaining their
regulatory phenotype and functions (23).
CONCLUDING REMARKS – FUTURE
ORIENTATIONS
We have identified, for the first time in humans, a mechanism
by which the gut microbiota can affect gut homeostasis: the
induction of DP8α Tregs in a mucosa exposed to frequent stim-
ulation with microbiota-derived immune stimuli, both PAMPs
and microbe antigens. The precise physiological significance of
DP8α Tregs remains to be determined, but the discovery of these
cells has potentially wide-ranging implications for the manage-
ment of IBD and, potentially, of other immune diseases involving
the abnormal induction and/or function of microbiota-induced
DP8α Tregs.
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